

#### TABLE OF CONTENTS FOR HEALTH AFFAIRS COMMITTEE

Committee Meeting: 2/8/2017

Board Meeting: 2/9/2017 Austin, Texas

Alex M. Cranberg, Chairman Ernest Aliseda David J. Beck Jeffery D. Hildebrand Sara Martinez Tucker

	Committee Meeting	Board Meeting	Page
Convene	9:30 a.m. Chairman Cranberg		
U. T. System Board of Regents: Discussion and appropriate action regarding Consent Agenda items, if any, assigned for Committee consideration	9:30 a.m. Discussion	Action	269
U. T. Rio Grande Valley: Report on the U. T. Rio Grande Valley School of Medicine	9:33 a.m.  Report/Discussion  President Bailey  Interim Dean Steven  Lieberman	Not on Agenda	270
3. U. T. M. D. Anderson Cancer Center: Report on Translational Research Accelerator, the research platform for the Moon Shots Program	9:53 a.m. <b>Report/Discussion</b> <i>President DePinho</i> <i>Dr. Andrew Futreal</i>	Not on Agenda	280
Adjourn	10:15 a.m.		

1. <u>U. T. System Board of Regents: Discussion and appropriate action regarding Consent Agenda items, if any, assigned for Committee consideration</u>

#### RECOMMENDATION

The proposed Consent Agenda items assigned to this Committee are on Pages 352 - 361.

#### 2. <u>U. T. Rio Grande Valley: Report on the U. T. Rio Grande Valley School of Medicine</u>

#### INTRODUCTION

President Guy Bailey, Ph.D., and Interim Dean Steven A. Lieberman, M.D., will report on the U. T. Rio Grande Valley School of Medicine. A PowerPoint presentation is set forth on the following pages.

#### **BACKGROUND INFORMATION**

In 2013, Senate Bill 24 authorized the creation of a new medical school in South Texas in association with a new general academic university, subsequently named The University of Texas Rio Grande Valley. On December 6, 2012, the U. T. System Board of Regents allocated \$10 million in Permanent University Funds annually for 10 years in support of the School of Medicine.

The School of Medicine received preliminary accreditation from the Liaison Committee on Medical Education in October 2015. A new medical education building was completed on the Edinburg campus in June 2016, and the first class of 55 students was welcomed in July 2016. The class includes 20 students originally from the Valley. Fifty-five percent of the students are from underrepresented minority groups.

The School's research enterprise is anchored by the South Texas Diabetes and Obesity Institute, which was established in 2014. External funding for this group increased from \$7 million to \$12.5 million from FY 2015 - 2016. Total external research funding for the School of Medicine was \$22.7 million in FY 2016.

The School's clinical enterprise is being developed in collaboration with several hospital partners throughout the Rio Grande Valley. Additional opportunities to provide health care services not currently available in the Valley are also being pursued.

The School of Medicine embraces the University's commitment to the community and looks to become a leader in the integration of community outreach, academic, and clinical programs to improve the health of people in the Rio Grande Valley.

This is the first report on the startup of the U. T. Rio Grande Valley School of Medicine.

# Report on the U. T. Rio Grande Valley School of Medicine

February 8-9, 2017 Meeting of the U. T. System Board of Regents - Health Affairs Committee

Guy Bailey, Ph.D., President Steven A. Lieberman, M.D., Interim Dean

U. T. System Board of Regents' Meeting Health Affairs Committee February 2017



## History and Milestones

2013 UTRGV and School of Medicine (SOM) aut	horized
---	---------

- 2014 South Texas Diabetes and Obesity Institute founded
- 2015 Four new residency programs opened
- 2015 Preliminary accreditation received from the Liaison Committee on Medical Education
- 2016 Medical education building completed in Edinburg
- 2016 Inaugural class of 55 seated
- 2016 Groundbreaking for new research building in McAllen



## Building the UTRGV SOM – Integrating all Four Missions

- Start with a population health lens
- Target major health needs of the Rio Grande Valley (RGV)
- Integrate programs within health need targets:
  - Recruit researchers
  - Develop residencies
  - Build clinical programs
  - Engage continuously with the community



## Undergraduate medical education

- Class of 2020
  - 55 students
  - 20 from the RGV
  - 55% underrepresented minorities
- Class of 2021
  - 3957 completed applications
  - 375 interviews



## **Graduate Medical Education**

	2016-2017	2017-2018
Residents	100	134
Programs	6	8
Specialties	4	6
Hospitals	3	4



## Research

Growth in external funding

- FY15: \$7,023,130

- FY16: \$22,706,110

- South Texas Diabetes and Obesity Institute Dr. Sarah Williams-Blangero
- Recruitment of Andrew Tsin, Ph.D., Associate Dean for Research and Chair, Department of Biomedical Sciences
- Groundbreaking on new research building in partnership with Doctors Hospital at Renaissance



## Clinical enterprise

- Unique clinical environment
- Opportunities:
  - Unavailable specialty services
  - Joint programs with hospital partners
- Current operations:
  - All Valley Lung Clinic
  - John Austin Peña Clinic
  - Mobile clinic



## Community Outreach

- UTRGV Community Hubs (in development)
- Population Health in collaboration with the U. T. Health Science Center - Houston School of Public Health, Brownsville
- Community Programs
  - Health fairs
  - Vaccination drives
  - "Unidos por nuestra salud" major community event in April
- Substantial grant funding



## Keys to success

1-2 years Build the team: faculty, administration

Clinical partnership maturation

Fill unmet specialty needs

3-5 years Clinical partnership success

External funding for initial health need targets

Throughout Constructive relationships with partners



## 3. <u>U. T. M. D. Anderson Cancer Center: Report on Translational Research Accelerator, the research platform for the Moon Shots Program</u>

#### **REPORT**

Ronald DePinho, M.D., President, and Andrew Futreal, Ph.D., Chair of Genomic Medicine at U. T. M. D. Anderson Cancer Center, will report on M. D. Anderson's Translational Research Accelerator, the research platform for the Moon Shots Program. A PowerPoint presentation is set forth on the following pages.

#### **BACKGROUND INFORMATION**

U. T. M. D. Anderson Cancer Center's Translational Research Accelerator (TRA) is a Moon Shot driven platform that has as its primary goal the full, near real-time integration of longitudinal patient-centric clinical and research data for the purposes of facilitating research and accelerating translation. TRA is custom-engineered on "industry" standard architecture to support advanced analytics and cloud integration. Specific attention to tools, interfaces, and visualization are coupled with dedicated computational personnel to help drive research. TRA's secondary goal is to become an infrastructure platform that can allow for real-time patient-centric analytics in the clinical setting. It serves as the backbone for a research paradigm shift with the goal to have every patient contributing to and potentially benefiting from research incorporating the Apollo platform, Moon Shots, and large scale genomics efforts (MDA10K). The Apollo platform is a research infrastructure to standardize longitudinal specimen collection, quality control, and molecular data generation.


# The University of Texas M. D. Anderson Cancer Center Translational Research Accelerator (TRA): Learning as much as possible from every patient

Ronald DePinho, M.D., President Andrew Futreal, Ph.D., Chair, Genomic Medicine

U. T. System Board of Regents' Meeting Health Affairs Committee February 2017


Agenda Book - 281

## Current state: Missing the opportunity to learn



THE UNIVERSITY OF TEXAS

# Purposeful organization and integration of clinical and research data



## Range of data types: Different demands

Making Cancer History\*

Agenda Book - 284

**NLP Tools** Required

#### Diagnosis codes

Fake ID	ENTRY_DAT	CODE	
34068	5/13/2001	41.85	
37660	8/6/2002	79.99	
140680	8/31/2003	79.99	
23315	5/14/2003	112	
75936	7/9/2004	117.9	

#### Lab tests

Fake ID	TEST	ENTRY_DAT	VALU
3536	pO2	1/23/1996	314
72921	LDL	2/5/1996	34
102460	pCO2	1/26/1996	45
135043	HDL	1/25/1996	35
135432	MonAb	1/24/1999	0.16

Structured

#### Problem lists:

- --- Medications known to be prescribed: Keppra 750 mg 1/2 tab q am and pm Dexilant 60 mg by mouth daily aspirin 325 mg 1 tablet by mouth daily clopidogrel 75 mg tablet 1 tablet by mouth daily
- --- Known adverse and allergic drug reactions: Sulfa Drugs
- --- known significant medical diagnoses: Seizure disorder Aneurysm Heartburn
- --- Known significant operative and invasive procedures: 2003 Appendectomy 2005 Stents put in \*\*DATE [Aug 29 05]

#### Clinical notes


EXAM: BILATERAL DIGITAL SCREENING MAMMOGRAM WITH CAD, "DATE[Mar 16 01]: COMPARISON: "DATE[Jul 01 01] TECHNIQUE: Standard CC and MLO views of both breasts were obtained. FINDINGS: The breast parenchyma is heterogeneously dense. The pattern is extremely complex with postsurgical change seen in the right upper outer quadrant and scattered benign-appearing calcification seen bilaterally. A possible asymmetry is seen in the superior aspect of the left breast. The parenchymal pattern otherwise remains stable bilaterally, with no new distortion or suspicious calcifications. IMPRESSION: RIGHT: No interval change. No current evidence of malignancy.. LEFT: Possible developing asymmetry superior aspect left breast for which further evaluation by true lateral and spot compression views recommended. Ultrasound may also be needed.. RECOMMENDATION: Left diagnostic mammogram with additional imaging as outlined above.. A left breast ultrasound may also be needed. BI-RADS Category 0: Incomplete Assessment - Need additional imaging evaluation. IMPRESSION: RIGHT: No interval change. No current evidence

Semi-structured Unstructured

of malignancy....

# Patient history from ingested data: A point of research departure


Making Cancer History\*



Agenda Book - 286

THE UNIVERSITY OF TEXAS

## TRA Framework



Agenda Book - 287

THE UNIVERSITY OF TEXAS


## TRA – Progress thus far

- All patients seen since 2012: 200,000 + patients' clinical data currently loaded into the system
- Currently rolling back a full 10 years 500K + patients
- 20,000 + patients with genomic data
- · Epic Integration going forward
- Common clinical data types
- All molecular testing data, gene panels, labs, medications, and other structured data
- Research data from Moon Shot Platforms (CGL, IMT currently)
- Geared for each new patient; all prior patients' data updated nightly/rolling forward
- Role-based, credentialed, and secure access in deployment
- Six computational biologists in place to facilitate investigation
- Beta-testers being on-boarded; data office open

## Translational Research Acceleration:

Agenda Book - 288

Every patient contributing to and potentially benefiting from research




Prevention, Diagnosis, Treatment, Management **Dissemination/Collaboration** 



Making Cancer History\*

Data Sharing – an approach: Purposeful, study-driven, strategic





Making Cancer History\*

## The Team

#### Leadership

Andy Futreal, Ph.D. – Director, Exec Sponsor Vinod Ravi, M.D. – Clinical Director

**MDACC** 

Brett Smith – Technical Director
Chris Belmont – Exec Sponsor

#### PMO

Sharlene Kmiec – PMO Greg Barbosa – PMO

#### IS/IT

Bryan Lari – IAI leadership Jeff Jin – IAI NLP manager Trey Kell – NLP Usamah Zaggar Alex Nguyen Sarah Duran David Qing Joann Tat

#### Comp Bio Team

John Zhang – leader Tatiana Karpinets Per Wu Terrence Wu Feng Wang Jun Li Lily Zhao Ethan Mao – cBIO

#### **PwC US**

#### Leadership

Mark Mynhier – Partner Mick Cody – Partner

#### Clinical informatics team

Rob Fassett, M.D. – Managing Director

Kelechi Nwoku, M.D. – Clinician Informaticist Harlan Stock, M.D. – Clinician

Informaticist

Rich Kenny, R.N. – Clinician Informaticist

#### Information delivery

Dhiraj Pathak – Managing Director Prabal Basu – Tech Lead Sahaya Bennet – Epic workstream lead

Shiv Narayanan – DQ, Analytics lead

Colin Balickie – Tech analyst Hannah Feldman – Tech analyst Kajal Tiwary – Tech analyst Prerna Bellara – Tech analyst Abhijeet Ghotra – Clinical analyst

#### **PMO**

Marcia Anderson – PM

#### **PwC Offshore (India)**

#### Clinical informatics team

Rishi Malhotra, M.D. – Clinician Informaticist Santosh Shah, M.D. – Clinician Informaticist Varsha Misra, M.D. – Clinician Informaticist Pooja Rajdev, Ph.D. – Bioinformaticist

#### **NLP** engineering

Aanchal Varma – Developer Anuj Goyal – Developer

### Data Ingestion, Data Quality, Tools

Ajimon Vishnumenon
Ganesh Alagarsamy
Janak Dev Prasad
Jyoti Agrawal
Krishna Priya Nukala
Madhusudan Yeggoni
Muthuraman Sethuraman
Raghuram Krishnamurthy
Rajesh Krishna Ra
Shashank Kulkarni
Smruthiya Vanchesan Sekar
Sree Mathi Ramakrishnan

#### VWB dev team

Aaditya Raj Arjun Bilimagga Sathish Basavaraja Kanayak Shiv Dinesh Ramakrishnan Gauray Chandra Ipsita Subudhi Monika Singh Nirmala Devi Dorairaian Padmanabha Varanchi Panneerselvam Palaniswamy Prathibha Rao Sandeep Bhatt Vinuthan Boralingaiah Habeebur Ansari Preeti Rahore Nithin Elias